290 related articles for article (PubMed ID: 9420020)
1. Antifolates in clinical development.
Takimoto CH
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-40-S18-51. PubMed ID: 9420020
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
3. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Semin Oncol; 1999 Apr; 26(2 Suppl 6):48-54. PubMed ID: 10598555
[TBL] [Abstract][Full Text] [Related]
4. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
5. Antifolates: the next millennium.
Allegra CJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-2. PubMed ID: 10598548
[No Abstract] [Full Text] [Related]
6. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
7. MTA, A Novel Multitargeted Antifolate: from preclinical to phase I and beyond. Proceedings of a meeting. Ixtapa, Mexico, March 13-15, 1998.
Semin Oncol; 1999 Apr; 26(2 Suppl 6):1-110. PubMed ID: 10610578
[No Abstract] [Full Text] [Related]
8. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
9. Antifolates: the next generation.
Fleming GF; Schilsky RL
Semin Oncol; 1992 Dec; 19(6):707-19. PubMed ID: 1462168
[TBL] [Abstract][Full Text] [Related]
10. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
11. [Pemetrexed: from preclinic to clinic].
Lansiaux A; Lokiec F
Bull Cancer; 2007; 94 Spec No Actualites():S134-8. PubMed ID: 17845983
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed: a multitargeted antifolate (ALIMTA, LY-231514).
Jones RJ; Twelves CJ
Expert Rev Anticancer Ther; 2002 Feb; 2(1):13-22. PubMed ID: 12113062
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of antitumor antifolates.
Newell DR
Semin Oncol; 1999 Apr; 26(2 Suppl 6):74-81. PubMed ID: 10598559
[TBL] [Abstract][Full Text] [Related]
14. Molecular, biochemical, and cellular pharmacology of pemetrexed.
Goldman ID; Zhao R
Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
[TBL] [Abstract][Full Text] [Related]
15. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed safety and dosing strategy.
Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
[TBL] [Abstract][Full Text] [Related]
18. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.
Chen VJ; Bewley JR; Andis SL; Schultz RM; Iversen PW; Shih C; Mendelsohn LG; Seitz DE; Tonkinson JL
Br J Cancer; 1998; 78 Suppl 3(Suppl 3):27-34. PubMed ID: 9717988
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed (Alimta): a promising new agent for the treatment of breast cancer.
Calvert H
Semin Oncol; 2003 Apr; 30(2 Suppl 3):2-5. PubMed ID: 12722017
[TBL] [Abstract][Full Text] [Related]
20. New antifolates in clinical development.
Takimoto CH; Allegra CJ
Oncology (Williston Park); 1995 Jul; 9(7):649-56, 659 DISC 660, 662, 665. PubMed ID: 8924375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]